<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02448121</url>
  </required_header>
  <id_info>
    <org_study_id>CAAE 25000039812/2005-99</org_study_id>
    <secondary_id>11738</secondary_id>
    <nct_id>NCT02448121</nct_id>
  </id_info>
  <brief_title>Autologous Bone Marrow Stem Cell Transplantation for Osteonecrosis in Sickle Cell Disease</brief_title>
  <official_title>Treatment for Hip, Knee, Ankle and Shoulder Osteonecrosis With Autologous Mononuclear Cells Transplantation in People With Sickle Cell Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Federal University of Bahia</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Hospital Universit√°rio Professor Edgard Santos</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Oswaldo Cruz Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Federal University of Bahia</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the safety and efficacy of autologous bone marrow
      stem cells in sickle cell disease patients with osteonecrosis
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The aim of this study is to evaluate autologous bone marrow stem cells transplantation as a
      safe and potentially beneficial treatment for sickle cell disease patients with
      osteonecrosis.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>August 2006</start_date>
  <completion_date type="Anticipated">August 2018</completion_date>
  <primary_completion_date type="Anticipated">July 2018</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Functional / Clinical Score of 10 points or more</measure>
    <time_frame>60 months</time_frame>
    <description>Standardized and objective scoring system to rate patient's functional abilities</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Numeric pain intensity scale (0-10)</measure>
    <time_frame>60 months</time_frame>
    <description>VAS scoring system</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease progression defined as progression to a fractural stage of osteonecrosis</measure>
    <time_frame>60 months</time_frame>
    <description>Radiographic signals</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Reoperation rate</measure>
    <time_frame>60 months</time_frame>
    <description>Need for further surgery or hip replacement</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Radiological progression</measure>
    <time_frame>60 months</time_frame>
    <description>Radiological progression is defined according to the development of the Ficat- and Steinberg-staging system of osteonecrosis. It is based on radiological findings in X-Ray and MRI scans, respectively, and it is useful in predicting outcomes.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Avascular Necrosis of Bone</condition>
  <condition>Sickle Cell Disease</condition>
  <arm_group>
    <arm_group_label>Autologous bone marrow stem cell graft</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Autologous bone marrow stem cell implantation</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Autologous bone marrow stem cell graft</intervention_name>
    <description>All patients will undergo autologous bone marrow stem cell implantation into the necrotic lesion area using a minimally invasive technique.</description>
    <arm_group_label>Autologous bone marrow stem cell graft</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Stable sickle cell disease patients

          -  FICAT classification of osteonecrosis, inclusive of Stage II.

          -  Diagnosis will be based on X-Ray and magnetic resonance imaging (MRI).

          -  No infection in affected bones at the time of surgery.

          -  Patient competent to give informed consent.

          -  Scoring at least 20 points on the pain and daily life activities questionnaire.

        Exclusion Criteria:

          -  FICAT stage III or more

          -  Patients with a history of corticosteroids or on active therapy

          -  Bone infection at the limb affected by necrosis

          -  Recurrent painful crises,

          -  Immunosuppressive drug therapy,

          -  Pregnancy,

          -  Presence of neoplastic disease or any other clinical concurrent condition other than
             sickle cell disease that predisposed them to the development of osteonecrosis of the
             femoral head
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>GIldasio Daltro, MD</last_name>
    <role>Study Director</role>
    <affiliation>Federal University of Bahia</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Vitor Fortuna, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Federal University of Bahia</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Roberto Meyer, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Federal University of Bahia</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Radovan Borojevic, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Federal University of Bahia</affiliation>
  </overall_official>
  <reference>
    <citation>Hernigou P, Daltro G, Filippini P, Mukasa MM, Manicom O. Percutaneous implantation of autologous bone marrow osteoprogenitor cells as treatment of bone avascular necrosis related to sickle cell disease. Open Orthop J. 2008 Apr 25;2:62-5. doi: 10.2174/1874325000802010062.</citation>
    <PMID>19478932</PMID>
  </reference>
  <reference>
    <citation>Hernigou P, Daltro G, Flouzat-Lachaniette CH, Roussignol X, Poignard A. Septic arthritis in adults with sickle cell disease often is associated with osteomyelitis or osteonecrosis. Clin Orthop Relat Res. 2010 Jun;468(6):1676-81. doi: 10.1007/s11999-009-1149-3. Epub 2009 Nov 3.</citation>
    <PMID>19885711</PMID>
  </reference>
  <reference>
    <citation>Hernigou P, Flouzat-Lachaniette CH, Daltro G, Galacteros F. Talar Osteonecrosis Related to Adult Sickle Cell Disease: Natural Evolution from Early to Late Stages. J Bone Joint Surg Am. 2016 Jul 6;98(13):1113-21. doi: 10.2106/JBJS.15.01074.</citation>
    <PMID>27385685</PMID>
  </reference>
  <results_reference>
    <citation>Daltro GC, Fortuna V, de Souza ES, Salles MM, Carreira AC, Meyer R, Freire SM, Borojevic R. Efficacy of autologous stem cell-based therapy for osteonecrosis of the femoral head in sickle cell disease: a five-year follow-up study. Stem Cell Res Ther. 2015 May 29;6:110. doi: 10.1186/s13287-015-0105-2.</citation>
    <PMID>26021713</PMID>
  </results_reference>
  <verification_date>November 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 15, 2015</study_first_submitted>
  <study_first_submitted_qc>May 18, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 19, 2015</study_first_posted>
  <last_update_submitted>November 17, 2017</last_update_submitted>
  <last_update_submitted_qc>November 17, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">November 20, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Federal University of Bahia</investigator_affiliation>
    <investigator_full_name>Vitor Fortuna</investigator_full_name>
    <investigator_title>PhD</investigator_title>
  </responsible_party>
  <keyword>Cell therapy</keyword>
  <keyword>Sickle cell disease</keyword>
  <keyword>Hip Osteonecrosis</keyword>
  <keyword>Autologous implantation</keyword>
  <keyword>Mesenchymal stromal cell</keyword>
  <keyword>Humeral Osteonecrosis</keyword>
  <keyword>Knee Osteonecrosis</keyword>
  <keyword>Ankle Osteonecrosis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anemia, Sickle Cell</mesh_term>
    <mesh_term>Necrosis</mesh_term>
    <mesh_term>Osteonecrosis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

